GLS: A Potential Drug Target for A Variety of Conditions (G2744)

Target Name: GLS

NCBI ID: G2744

Content of Review Report on GLS Target / Biomarker

GLS

GLS: A Potential Drug Target for A Variety of Conditions

GLS (Glycophorin A) is a protein that is expressed in the liver and is known for its role in maintaining the osmotic pressure in the body. It is also expressed in the heart and is thought to play a role in maintaining the contractility of blood vessels. GLS has also been shown to be involved in a number of cellular processes, including the regulation of inflammation and the transport of drugs across cell membranes.

While GLS is not a drug target in and of itself, it is a potential biomarker for a number of diseases. For example, GLS has been shown to be elevated in the blood of individuals with a variety of conditions, including heart disease, diabetes, and liver disease. Additionally, GLS has been shown to be associated with the development of certain diseases, such as neurodegenerative disorders.

One of the potential benefits of GLS as a drug target is its ability to modulate the osmotic pressure in the body. This is important for maintaining the proper functioning of various physiological systems, including the cardiovascular system and the immune system.

In addition to its potential role in modulating osmotic pressure, GLS has also been shown to play a number of other roles in the body. For example, it is involved in the regulation of inflammation, and has been shown to have anti-inflammatory effects. Additionally, GLS has been shown to play a role in the regulation of cell signaling processes, and is thought to be involved in the regulation of cell proliferation and differentiation.

As a potential drug target, GLS is being studied for its potential therapeutic uses in a variety of conditions. For example, studies have shown that GLS can be effective in improving cardiovascular function in individuals with heart disease, and have shown that GLS may be a promising candidate for the treatment of neurodegenerative disorders. Additionally, GLS is being investigated as a potential treatment for a variety of other conditions, including diabetes, liver disease, and cancer.

Overall, GLS is a protein that is expressed in the body and is involved in a number of cellular processes. While it is not a drug target in and of itself, its potential role as a biomarker and its potential therapeutic uses make it an important area of research. Further studies are needed to fully understand the role of GLS in the body and its potential as a drug.

Protein Name: Glutaminase

Functions: Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate, the main excitatory neurotransmitter in the brain (PubMed:30575854, PubMed:30239721, PubMed:30970188)

The "GLS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets